Global Hip Osteoarthritis Pain Drug Market Insights and Forecast to 2026
1 Study Coverage
- 1.1 Hip Osteoarthritis Pain Drug Product Introduction
- 1.2 Market Segments
- 1.3 Key Hip Osteoarthritis Pain Drug Manufacturers Covered: Ranking by Revenue
- 1.4 Market by Type
- 1.4.1 Global Hip Osteoarthritis Pain Drug Market Size Growth Rate by Type
- 1.4.2 Oral
- 1.4.3 Injection
- 1.4.4 External
- 1.5 Market by Application
- 1.5.1 Global Hip Osteoarthritis Pain Drug Market Size Growth Rate by Application
- 1.5.2 Medical Care
- 1.5.3 Personal Care
- 1.6 Study Objectives
- 1.7 Years Considered
2 Executive Summary
- 2.1 Global Hip Osteoarthritis Pain Drug Market Size, Estimates and Forecasts
- 2.1.1 Global Hip Osteoarthritis Pain Drug Revenue 2015-2026
- 2.1.2 Global Hip Osteoarthritis Pain Drug Sales 2015-2026
- 2.2 Global Hip Osteoarthritis Pain Drug, Market Size by Producing Regions: 2015 VS 2020 VS 2026
- 2.2.1 Global Hip Osteoarthritis Pain Drug Retrospective Market Scenario in Sales by Region: 2015-2020
- 2.2.2 Global Hip Osteoarthritis Pain Drug Retrospective Market Scenario in Revenue by Region: 2015-2020
3 Global Hip Osteoarthritis Pain Drug Competitor Landscape by Players
- 3.1 Hip Osteoarthritis Pain Drug Sales by Manufacturers
- 3.1.1 Hip Osteoarthritis Pain Drug Sales by Manufacturers (2015-2020)
- 3.1.2 Hip Osteoarthritis Pain Drug Sales Market Share by Manufacturers (2015-2020)
- 3.2 Hip Osteoarthritis Pain Drug Revenue by Manufacturers
- 3.2.1 Hip Osteoarthritis Pain Drug Revenue by Manufacturers (2015-2020)
- 3.2.2 Hip Osteoarthritis Pain Drug Revenue Share by Manufacturers (2015-2020)
- 3.2.3 Global Hip Osteoarthritis Pain Drug Market Concentration Ratio (CR5 and HHI) (2015-2020)
- 3.2.4 Global Top 10 and Top 5 Companies by Hip Osteoarthritis Pain Drug Revenue in 2019
- 3.2.5 Global Hip Osteoarthritis Pain Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
- 3.3 Hip Osteoarthritis Pain Drug Price by Manufacturers
- 3.4 Hip Osteoarthritis Pain Drug Manufacturing Base Distribution, Product Types
- 3.4.1 Hip Osteoarthritis Pain Drug Manufacturers Manufacturing Base Distribution, Headquarters
- 3.4.2 Manufacturers Hip Osteoarthritis Pain Drug Product Type
- 3.4.3 Date of International Manufacturers Enter into Hip Osteoarthritis Pain Drug Market
- 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
- 4.1 Global Hip Osteoarthritis Pain Drug Market Size by Type (2015-2020)
- 4.1.1 Global Hip Osteoarthritis Pain Drug Sales by Type (2015-2020)
- 4.1.2 Global Hip Osteoarthritis Pain Drug Revenue by Type (2015-2020)
- 4.1.3 Hip Osteoarthritis Pain Drug Average Selling Price (ASP) by Type (2015-2026)
- 4.2 Global Hip Osteoarthritis Pain Drug Market Size Forecast by Type (2021-2026)
- 4.2.1 Global Hip Osteoarthritis Pain Drug Sales Forecast by Type (2021-2026)
- 4.2.2 Global Hip Osteoarthritis Pain Drug Revenue Forecast by Type (2021-2026)
- 4.2.3 Hip Osteoarthritis Pain Drug Average Selling Price (ASP) Forecast by Type (2021-2026)
- 4.3 Global Hip Osteoarthritis Pain Drug Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End
5 Market Size by Application (2015-2026)
- 5.1 Global Hip Osteoarthritis Pain Drug Market Size by Application (2015-2020)
- 5.1.1 Global Hip Osteoarthritis Pain Drug Sales by Application (2015-2020)
- 5.1.2 Global Hip Osteoarthritis Pain Drug Revenue by Application (2015-2020)
- 5.1.3 Hip Osteoarthritis Pain Drug Price by Application (2015-2020)
- 5.2 Hip Osteoarthritis Pain Drug Market Size Forecast by Application (2021-2026)
- 5.2.1 Global Hip Osteoarthritis Pain Drug Sales Forecast by Application (2021-2026)
- 5.2.2 Global Hip Osteoarthritis Pain Drug Revenue Forecast by Application (2021-2026)
- 5.2.3 Global Hip Osteoarthritis Pain Drug Price Forecast by Application (2021-2026)
6 North America
- 6.1 North America Hip Osteoarthritis Pain Drug by Country
- 6.1.1 North America Hip Osteoarthritis Pain Drug Sales by Country
- 6.1.2 North America Hip Osteoarthritis Pain Drug Revenue by Country
- 6.1.3 U.S.
- 6.1.4 Canada
- 6.2 North America Hip Osteoarthritis Pain Drug Market Facts & Figures by Type
- 6.3 North America Hip Osteoarthritis Pain Drug Market Facts & Figures by Application
7 Europe
- 7.1 Europe Hip Osteoarthritis Pain Drug by Country
- 7.1.1 Europe Hip Osteoarthritis Pain Drug Sales by Country
- 7.1.2 Europe Hip Osteoarthritis Pain Drug Revenue by Country
- 7.1.3 Germany
- 7.1.4 France
- 7.1.5 U.K.
- 7.1.6 Italy
- 7.1.7 Russia
- 7.2 Europe Hip Osteoarthritis Pain Drug Market Facts & Figures by Type
- 7.3 Europe Hip Osteoarthritis Pain Drug Market Facts & Figures by Application
8 Asia Pacific
- 8.1 Asia Pacific Hip Osteoarthritis Pain Drug by Region
- 8.1.1 Asia Pacific Hip Osteoarthritis Pain Drug Sales by Region
- 8.1.2 Asia Pacific Hip Osteoarthritis Pain Drug Revenue by Region
- 8.1.3 China
- 8.1.4 Japan
- 8.1.5 South Korea
- 8.1.6 India
- 8.1.7 Australia
- 8.1.8 Taiwan
- 8.1.9 Indonesia
- 8.1.10 Thailand
- 8.1.11 Malaysia
- 8.1.12 Philippines
- 8.1.13 Vietnam
- 8.2 Asia Pacific Hip Osteoarthritis Pain Drug Market Facts & Figures by Type
- 8.3 Asia Pacific Hip Osteoarthritis Pain Drug Market Facts & Figures by Application
9 Latin America
- 9.1 Latin America Hip Osteoarthritis Pain Drug by Country
- 9.1.1 Latin America Hip Osteoarthritis Pain Drug Sales by Country
- 9.1.2 Latin America Hip Osteoarthritis Pain Drug Revenue by Country
- 9.1.3 Mexico
- 9.1.4 Brazil
- 9.1.5 Argentina
- 9.2 Central & South America Hip Osteoarthritis Pain Drug Market Facts & Figures by Type
- 9.3 Central & South America Hip Osteoarthritis Pain Drug Market Facts & Figures by Application
10 Middle East and Africa
- 10.1 Middle East and Africa Hip Osteoarthritis Pain Drug by Country
- 10.1.1 Middle East and Africa Hip Osteoarthritis Pain Drug Sales by Country
- 10.1.2 Middle East and Africa Hip Osteoarthritis Pain Drug Revenue by Country
- 10.1.3 Turkey
- 10.1.4 Saudi Arabia
- 10.1.5 U.A.E
- 10.2 Middle East and Africa Hip Osteoarthritis Pain Drug Market Facts & Figures by Type
- 10.3 Middle East and Africa Hip Osteoarthritis Pain Drug Market Facts & Figures by Application
11 Company Profiles
- 11.1 Pfizer
- 11.1.1 Pfizer Corporation Information
- 11.1.2 Pfizer Description and Business Overview
- 11.1.3 Pfizer Sales, Revenue and Gross Margin (2015-2020)
- 11.1.4 Pfizer Hip Osteoarthritis Pain Drug Products Offered
- 11.1.5 Pfizer Related Developments
- 11.2 Johnson and Johnson
- 11.2.1 Johnson and Johnson Corporation Information
- 11.2.2 Johnson and Johnson Description and Business Overview
- 11.2.3 Johnson and Johnson Sales, Revenue and Gross Margin (2015-2020)
- 11.2.4 Johnson and Johnson Hip Osteoarthritis Pain Drug Products Offered
- 11.2.5 Johnson and Johnson Related Developments
- 11.3 GlaxoSmithKline
- 11.3.1 GlaxoSmithKline Corporation Information
- 11.3.2 GlaxoSmithKline Description and Business Overview
- 11.3.3 GlaxoSmithKline Sales, Revenue and Gross Margin (2015-2020)
- 11.3.4 GlaxoSmithKline Hip Osteoarthritis Pain Drug Products Offered
- 11.3.5 GlaxoSmithKline Related Developments
- 11.4 Bayer
- 11.4.1 Bayer Corporation Information
- 11.4.2 Bayer Description and Business Overview
- 11.4.3 Bayer Sales, Revenue and Gross Margin (2015-2020)
- 11.4.4 Bayer Hip Osteoarthritis Pain Drug Products Offered
- 11.4.5 Bayer Related Developments
- 11.5 Eli Lilly
- 11.5.1 Eli Lilly Corporation Information
- 11.5.2 Eli Lilly Description and Business Overview
- 11.5.3 Eli Lilly Sales, Revenue and Gross Margin (2015-2020)
- 11.5.4 Eli Lilly Hip Osteoarthritis Pain Drug Products Offered
- 11.5.5 Eli Lilly Related Developments
- 11.6 Novartis
- 11.6.1 Novartis Corporation Information
- 11.6.2 Novartis Description and Business Overview
- 11.6.3 Novartis Sales, Revenue and Gross Margin (2015-2020)
- 11.6.4 Novartis Hip Osteoarthritis Pain Drug Products Offered
- 11.6.5 Novartis Related Developments
- 11.7 Sanofi
- 11.7.1 Sanofi Corporation Information
- 11.7.2 Sanofi Description and Business Overview
- 11.7.3 Sanofi Sales, Revenue and Gross Margin (2015-2020)
- 11.7.4 Sanofi Hip Osteoarthritis Pain Drug Products Offered
- 11.7.5 Sanofi Related Developments
- 11.8 Horizon Pharma
- 11.8.1 Horizon Pharma Corporation Information
- 11.8.2 Horizon Pharma Description and Business Overview
- 11.8.3 Horizon Pharma Sales, Revenue and Gross Margin (2015-2020)
- 11.8.4 Horizon Pharma Hip Osteoarthritis Pain Drug Products Offered
- 11.8.5 Horizon Pharma Related Developments
- 11.9 Abbott
- 11.9.1 Abbott Corporation Information
- 11.9.2 Abbott Description and Business Overview
- 11.9.3 Abbott Sales, Revenue and Gross Margin (2015-2020)
- 11.9.4 Abbott Hip Osteoarthritis Pain Drug Products Offered
- 11.9.5 Abbott Related Developments
- 11.10 Mylan
- 11.10.1 Mylan Corporation Information
- 11.10.2 Mylan Description and Business Overview
- 11.10.3 Mylan Sales, Revenue and Gross Margin (2015-2020)
- 11.10.4 Mylan Hip Osteoarthritis Pain Drug Products Offered
- 11.10.5 Mylan Related Developments
- 11.1 Pfizer
- 11.1.1 Pfizer Corporation Information
- 11.1.2 Pfizer Description and Business Overview
- 11.1.3 Pfizer Sales, Revenue and Gross Margin (2015-2020)
- 11.1.4 Pfizer Hip Osteoarthritis Pain Drug Products Offered
- 11.1.5 Pfizer Related Developments
- 11.12 TEVA
- 11.12.1 TEVA Corporation Information
- 11.12.2 TEVA Description and Business Overview
- 11.12.3 TEVA Sales, Revenue and Gross Margin (2015-2020)
- 11.12.4 TEVA Products Offered
- 11.12.5 TEVA Related Developments
- 11.13 Almatica Pharma
- 11.13.1 Almatica Pharma Corporation Information
- 11.13.2 Almatica Pharma Description and Business Overview
- 11.13.3 Almatica Pharma Sales, Revenue and Gross Margin (2015-2020)
- 11.13.4 Almatica Pharma Products Offered
- 11.13.5 Almatica Pharma Related Developments
- 11.14 Astellas Pharma
- 11.14.1 Astellas Pharma Corporation Information
- 11.14.2 Astellas Pharma Description and Business Overview
- 11.14.3 Astellas Pharma Sales, Revenue and Gross Margin (2015-2020)
- 11.14.4 Astellas Pharma Products Offered
- 11.14.5 Astellas Pharma Related Developments
- 11.15 Tide Pharmaceutical
- 11.15.1 Tide Pharmaceutical Corporation Information
- 11.15.2 Tide Pharmaceutical Description and Business Overview
- 11.15.3 Tide Pharmaceutical Sales, Revenue and Gross Margin (2015-2020)
- 11.15.4 Tide Pharmaceutical Products Offered
- 11.15.5 Tide Pharmaceutical Related Developments
- 11.16 Iroko Pharmaceuticals
- 11.16.1 Iroko Pharmaceuticals Corporation Information
- 11.16.2 Iroko Pharmaceuticals Description and Business Overview
- 11.16.3 Iroko Pharmaceuticals Sales, Revenue and Gross Margin (2015-2020)
- 11.16.4 Iroko Pharmaceuticals Products Offered
- 11.16.5 Iroko Pharmaceuticals Related Developments
- 11.17 Hengrui Pharmaceutical
- 11.17.1 Hengrui Pharmaceutical Corporation Information
- 11.17.2 Hengrui Pharmaceutical Description and Business Overview
- 11.17.3 Hengrui Pharmaceutical Sales, Revenue and Gross Margin (2015-2020)
- 11.17.4 Hengrui Pharmaceutical Products Offered
- 11.17.5 Hengrui Pharmaceutical Related Developments
- 11.18 Abiogen Pharma
- 11.18.1 Abiogen Pharma Corporation Information
- 11.18.2 Abiogen Pharma Description and Business Overview
- 11.18.3 Abiogen Pharma Sales, Revenue and Gross Margin (2015-2020)
- 11.18.4 Abiogen Pharma Products Offered
- 11.18.5 Abiogen Pharma Related Developments
12 Future Forecast by Regions (Countries) (2021-2026)
- 12.1 Hip Osteoarthritis Pain Drug Market Estimates and Projections by Region
- 12.1.1 Global Hip Osteoarthritis Pain Drug Sales Forecast by Regions 2021-2026
- 12.1.2 Global Hip Osteoarthritis Pain Drug Revenue Forecast by Regions 2021-2026
- 12.2 North America Hip Osteoarthritis Pain Drug Market Size Forecast (2021-2026)
- 12.2.1 North America: Hip Osteoarthritis Pain Drug Sales Forecast (2021-2026)
- 12.2.2 North America: Hip Osteoarthritis Pain Drug Revenue Forecast (2021-2026)
- 12.2.3 North America: Hip Osteoarthritis Pain Drug Market Size Forecast by Country (2021-2026)
- 12.3 Europe Hip Osteoarthritis Pain Drug Market Size Forecast (2021-2026)
- 12.3.1 Europe: Hip Osteoarthritis Pain Drug Sales Forecast (2021-2026)
- 12.3.2 Europe: Hip Osteoarthritis Pain Drug Revenue Forecast (2021-2026)
- 12.3.3 Europe: Hip Osteoarthritis Pain Drug Market Size Forecast by Country (2021-2026)
- 12.4 Asia Pacific Hip Osteoarthritis Pain Drug Market Size Forecast (2021-2026)
- 12.4.1 Asia Pacific: Hip Osteoarthritis Pain Drug Sales Forecast (2021-2026)
- 12.4.2 Asia Pacific: Hip Osteoarthritis Pain Drug Revenue Forecast (2021-2026)
- 12.4.3 Asia Pacific: Hip Osteoarthritis Pain Drug Market Size Forecast by Region (2021-2026)
- 12.5 Latin America Hip Osteoarthritis Pain Drug Market Size Forecast (2021-2026)
- 12.5.1 Latin America: Hip Osteoarthritis Pain Drug Sales Forecast (2021-2026)
- 12.5.2 Latin America: Hip Osteoarthritis Pain Drug Revenue Forecast (2021-2026)
- 12.5.3 Latin America: Hip Osteoarthritis Pain Drug Market Size Forecast by Country (2021-2026)
- 12.6 Middle East and Africa Hip Osteoarthritis Pain Drug Market Size Forecast (2021-2026)
- 12.6.1 Middle East and Africa: Hip Osteoarthritis Pain Drug Sales Forecast (2021-2026)
- 12.6.2 Middle East and Africa: Hip Osteoarthritis Pain Drug Revenue Forecast (2021-2026)
- 12.6.3 Middle East and Africa: Hip Osteoarthritis Pain Drug Market Size Forecast by Country (2021-2026)
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
- 13.1 Market Opportunities and Drivers
- 13.2 Market Challenges
- 13.3 Market Risks/Restraints
- 13.4 Porter's Five Forces Analysis
- 13.5 Primary Interviews with Key Hip Osteoarthritis Pain Drug Players (Opinion Leaders)
14 Value Chain and Sales Channels Analysis
- 14.1 Value Chain Analysis
- 14.2 Hip Osteoarthritis Pain Drug Customers
- 14.3 Sales Channels Analysis
- 14.3.1 Sales Channels
- 14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
- 16.1 Research Methodology
- 16.1.1 Methodology/Research Approach
- 16.1.2 Data Source
- 16.2 Author Details
Hip Osteoarthritis Pain Drug market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Hip Osteoarthritis Pain Drug market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.
Segment by Type, the Hip Osteoarthritis Pain Drug market is segmented into
Oral
Injection
External
Segment by Application, the Hip Osteoarthritis Pain Drug market is segmented into
Medical Care
Personal Care
Regional and Country-level Analysis
The Hip Osteoarthritis Pain Drug market is analysed and market size information is provided by regions (countries).
The key regions covered in the Hip Osteoarthritis Pain Drug market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape and Hip Osteoarthritis Pain Drug Market Share Analysis
Hip Osteoarthritis Pain Drug market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Hip Osteoarthritis Pain Drug business, the date to enter into the Hip Osteoarthritis Pain Drug market, Hip Osteoarthritis Pain Drug product introduction, recent developments, etc.
The major vendors covered:
Pfizer
Johnson and Johnson
GlaxoSmithKline
Bayer
Eli Lilly
Novartis
Sanofi
Horizon Pharma
Abbott
Mylan
Daiichi Sankyo
TEVA
Almatica Pharma
Astellas Pharma
Tide Pharmaceutical
Iroko Pharmaceuticals
Hengrui Pharmaceutical
Abiogen Pharma